Log in to search using one of your social media accounts:

 

Chiasma Announces Completion of $70 Million Series E Financing

NEWTON, Mass. and JERUSALEM, Feb. 27, 2015 -- (Healthcare Sales &Marketing Network) -- Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closin... Biopharmaceuticals, Venture CapitalChiasma, octreotide capsules, acromegaly
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion: Our results confirm OSAS as a common disorder in acromegaly patients as well as PAP therapy being required for a majority of patients. Therefore, all acromegaly patients should be assessed in terms of OSAS and be followed closely for the evaluation of PAP adherence. PMID: 29151303 [PubMed]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Endocrine Practice, Ahead of Print.
Source: Endocrine Practice - Category: Endocrinology Authors: Source Type: research
Endocrine Practice, Ahead of Print.
Source: Endocrine Practice - Category: Endocrinology Authors: Source Type: research
We aimed to determine the long-term effects of Gamma knife radiosurgery (GKS) on remnants in the cavernous sinus (CS) after transsphenoidal surgery (TSS) for acromegaly and to identify its possible adverse effects.
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Original article Source Type: research
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Conclusions: Switching to PAS-LAR, either as monotherapy, or combination with pegvisomant, can control IGF-I levels in the majority of patients. PAS-LAR demonstrated a pegvisomant sparing effect of 66% compared to the combination with LA-SSAs. Hyperglycemia was the most important safety issue. PMID: 29155991 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Conclusion: Reduction in growth hormone levels and insulin-like growth factor type 1 can decrease the LVM and LVMI, which directly or indirectly contributes to the improvement in diastolic as well as systolic function and probably mortality.
Source: Neurology India - Category: Neurology Authors: Source Type: research
Subhash Yadav, Eesh BhatiaNeurology India 2017 65(6):1223-1224
Source: Neurology India - Category: Neurology Authors: Source Type: research
Antonio Ribeiro-Oliveira, Márta Korbonits, Claudia M V FreireNeurology India 2017 65(6):1225-1226
Source: Neurology India - Category: Neurology Authors: Source Type: research
ConclusionsThe results from these long-term placebo-controlled studies confirm the established safety profile of long-acting OCT, in particular low risk of cardiac, hepatic and renal toxicity in a high-risk population.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Acromegaly | Marketing | Pharmaceuticals